LitCovid-sentences  

PMC:7195088 / 15642-20795 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T97 91-132 Sentence denotes Open-label RCT (NCT04307693, recruiting).
T98 133-192 Sentence denotes Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.
T99 193-296 Sentence denotes • Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae.
T100 297-346 Sentence denotes Open-label RCT (NCT04261907, not yet recruiting).
T101 347-516 Sentence denotes Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).
T102 517-619 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19.
T103 620-661 Sentence denotes Open-label RCT (NCT04252885, recruiting).
T104 662-738 Sentence denotes Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.
T105 739-864 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19.
T106 865-906 Sentence denotes Open-label RCT (NCT04276688, recruiting).
T107 907-989 Sentence denotes Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).
T108 990-1133 Sentence denotes • Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia.
T109 1134-1175 Sentence denotes Open-label RCT (NCT04255017, recruiting).
T110 1176-1451 Sentence denotes Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 > 93% or Pao 2/Fio 2 > 300 mm Hg); (b) time to lung recovery.
T111 1452-1564 Sentence denotes • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19.
T112 1565-1616 Sentence denotes Double-blind RCT (NCT04328285, not yet recruiting).
T113 1617-1711 Sentence denotes Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).
T114 1712-1828 Sentence denotes • Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia.
T115 1829-1878 Sentence denotes Open-label RCT (NCT04286503, not yet recruiting).
T116 1879-2061 Sentence denotes Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.
T117 2062-2244 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19.
T118 2245-2294 Sentence denotes Open-label RCT (NCT04295551, not yet recruiting).
T119 2295-2356 Sentence denotes Primary endpoint: clinical recovery time (follow-up 28 days).
T120 2357-2526 Sentence denotes • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19.
T121 2527-2576 Sentence denotes Open-label RCT (NCT04275388, not yet recruiting).
T122 2577-2638 Sentence denotes Primary endpoint: clinical recovery time (follow-up 14 days).
T123 2639-2818 Sentence denotes • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19.
T124 2819-2860 Sentence denotes Open-label RCT (NCT04251871, recruiting).
T125 2861-2938 Sentence denotes Primary endpoint: time to complete remission of symptoms (follow-up 28 days).
T126 2939-3154 Sentence denotes • Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia.
T127 3155-3208 Sentence denotes Partly blinded RCT (NCT04331470, not yet recruiting).
T128 3209-3290 Sentence denotes Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.
T129 3291-3402 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19.
T130 3403-3464 Sentence denotes Double-blind, adaptive RCT (NCT04328012, not yet recruiting).
T131 3465-3541 Sentence denotes Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).
T132 3542-3711 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19.
T133 3712-3765 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T134 3766-3837 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.
T135 3838-4137 Sentence denotes • Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19.
T136 4138-4189 Sentence denotes Single-blind RCT (NCT04323345, not yet recruiting).
T137 4190-4383 Sentence denotes Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).
T138 4384-4521 Sentence denotes • Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19.
T139 4522-4571 Sentence denotes Open-label RCT (NCT04328480, not yet recruiting).
T140 4572-4630 Sentence denotes Primary endpoint: all-cause mortality (follow-up 30 days).
T141 4631-5035 Sentence denotes • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19.
T142 5036-5085 Sentence denotes Open-label RCT (NCT04303299, not yet recruiting).
T143 5086-5153 Sentence denotes Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).